Director, Prevention and Early Intervention Program for Psychoses
ashok_dot_malla_At_douglas_dot_mcgill_dot_ca |
2013
Anderson K. K., Fuhrer R., Malla A. (2013). "There are too many steps before you get to where you need to be": help-seeking by patients with first-episode psychosis, J Ment Health, 22(4), 384-95. Find out more.
Anderson K. K., Fuhrer R., Schmitz N., Malla A. (2013). Determinants of negative pathways to care and their impact on service disengagement in first-episode psychosis, Soc Psychiatry Psychiatr Epidemiol, 48(1), 125-36. Find out more.
Anderson K. K., Fuhrer R., Wynant W., Abrahamowicz M., Buckeridge D. L., Malla A. (2013). Patterns of health services use prior to a first diagnosis of psychosis: the importance of primary care, Soc Psychiatry Psychiatr Epidemiol, 48(9), 1389-98. Find out more.
Badawi G., Page V., Smith K. J., Gariepy G., Malla A., Wang J., Boyer R., Strychar I., Lesage A., Ying Kin N. (2013). Self-rated health: a predictor for the three year incidence of major depression in individuals with Type II diabetes, J Affect Disord, 145(1), 100-5. Find out more.
Braehler C., Valiquette L., Holowka D., Malla A., Joober R., Ciampi A., Pawliuk N., King S. (2013). Childhood trauma and dissociation in first-episode psychosis, chronic schizophrenia and community controls, Psychiatry Res, 210(1), 36-42. Find out more.
Chue P., Malla A., Bouchard R. H., Lessard S., Ganesan S., Stip E., Johnson S., Chen E., Ahn Y. M., Kim Y. S., Robinson G., Schweikert C., Gendron A., Eriksson H. (2013). The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia, Curr Med Res Opin, 29(3), 227-39. Find out more.
Gardner D. M., Murphy A. L., Kutcher S., Beaulieu S., Carandang C., Labelle A., Lalonde P., Malla A., Milliken H., O'Donovan C., Schaffer A., Soni J., Taylor V. H., Williams R. (2013). Evidence review and clinical guidance for the use of ziprasidone in Canada, Ann Gen Psychiatry, 12(1), 1. Find out more.
Hovington C.L., Bodnar M., Joober R., Malla A., Lepage M. (2013). Impairment in verbal memory observed in first episode psychosis patients with persistent negative symptoms, Schizophr Res, 147(2-3), 223-229. Find out more.
Iyer S., Banks N., Roy M. A., Tibbo P., Williams R., Manchanda R., Chue P., Malla A. (2013). A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives, Can J Psychiatry, 58(5 Suppl 1), 14S-22S. Find out more.
Lal S., Ungar M., Leggo C., Malla A., Frankish J., Suto M. J. (2013). Well-being and engagement in valued activities: experiences of young people with psychosis, OTJR (Thorofare N J), 33(4), 190-7. Find out more.
Latimer E., Wynant W., Clark R., Malla A., Moodie E., Tamblyn R., Naidu A. (2013). Underprescribing of Clozapine and Unexplained Variation in Use across Hospitals and Regions in the Canadian Province of Quebec, Clin Schizophr Relat Psychoses, 7(1), 33-41. Find out more.
Malla A. (2013). Commentary on "Did Christianity cause schizophrenia?", Transcult Psychiatry, 50(3), 426-9. Find out more.
Malla A., Chue P., Jordan G., Stip E., Koczerginski D., Milliken H., Joseph A., Williams R., Adams B., Manchanda R., Oyewumi K., Roy M. A. (2013). An Exploratory Open-Label Randomized Trial Comparing Risperidone Long Acting Injectable (RLAI) with Oral Antipsychotic Medication in the Treatment of Early Psychosis, Clin Schizophr Relat Psychoses, 1-26. Find out more.
Malla A., Tibbo P., Chue P., Levy E., Manchanda R., Teehan M., Williams R., Iyer S., Roy M. A. (2013). Long-acting injectable antipsychotics: recommendations for clinicians, Can J Psychiatry, 58(5 Suppl 1), 30S-5S. Find out more.
Manchanda R., Chue P., Malla A., Tibbo P., Roy M. A., Williams R., Iyer S., Lutgens D., Banks N. (2013). Long-acting injectable antipsychotics: evidence of effectiveness and use, Can J Psychiatry, 58(5 Suppl 1), 5S-13S. Find out more.
Messier L., Elisha B., Schmitz N., Gariepy G., Malla A., Lesage A., Boyer R., Wang J., Strychar I. (2013). Changes in depressive symptoms and changes in lifestyle-related indicators: a 1-year follow-up study among adults with type 2 diabetes in quebec, Canadian Journal of Diabetes, 37(4), 243-8. Find out more.
Montreuil T. C., Malla A., Joober R., Belanger C., Lepage M. (2013). Anxiety symptoms severity and short-term clinical outcome in first-episode psychosis, Early Interv Psychiatry, 7(1), 5-11. Find out more.
Pira S., Durr G., Pawliuk N., Joober R., Malla A. (2013). Mode of entry to an early intervention service for psychotic disorders: determinants and impact on outcome, Psychiatr Serv, 64(11), 1166-9. Find out more.
Pope M. A., Joober R., Malla A. (2013). Diagnostic stability of first-episode psychotic disorders and persistence of comorbid psychiatric disorders over 1 year, Can J Psychiatry, 58(10), 588-94. Find out more.
Pruessner M., Bechard-Evans L., Boekestyn L., Iyer S.N., Pruessner J., Malla A. (2013). Attenuated cortisol response to acute psychosocial stress in individuals at ultra-high risk for psychosis, Schizophr Res, 146(1-3), 79-86. Find out more.